Protease inhibitor-induced diabetic complications: Incidence, management and prevention

Drug Safety

Volumn 28, Issue 3, 2005, Pages 209-226

  Lien, Lillian F ^a   Feinglos, Mark N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BEZAFIBRATE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; INDINAVIR; INSULIN; LEPTIN; METFORMIN; MOZENAVIR; NEVIRAPINE; NEW DRUG; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; TIPRANAVIR; TROGLITAZONE;

ACANTHOSIS NIGRICANS; BODY FAT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPEROSMOLAR COMA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN TREATMENT; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; PATIENT MONITORING; PHYSICAL ACTIVITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW;

DIABETES COMPLICATIONS; DRUG THERAPY; HUMANS; HYPERGLYCEMIA; PROTEASE INHIBITORS;

EID: 14944351947     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528030-00003     Document Type: Review

References (71)

1. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997 Nov; 127 (10): 947
2. Lee EC, Walmsley S, Fantus IG, et al. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. CMAJ 1999; 161: 161-4
3. Kan VL, Nylen ES. Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance. AIDS 1999; 13: 1987-9
4. Hughes C, Taylor G. Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 877-80
5. Eastone JA, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor [letter]. Ann Intern Med 1997; 127: 948
6. Dube MP, Johnson DL, Currier JS, et al. Protease inhibitor-associated hyperglycaemia. Lancet 1997 Sep 6; 350: 713-4
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8
8. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 Jun 19; 353: 2093-9
9. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70
10. Paparizos VA, Kyriakis KP, Botsis C, et al. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000; 14: 903-5
11. Dever L, Oruwari PA, Figueroa WE, et al. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000; 34: 580-4
12. Palma-Aguirre A, Halabe-Cherem J, Nellen-Hummel H, et al. Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection. Arch Med Res 2000; 31: 81-4
13. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 2050-6
14. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396-405
15. Murray M, Lumpkin MD. FDA Public Health Advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Bethesda (MD): Food and Drug Administration, 1997
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus on behalf of the American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998 Jan; 21 (1 Suppl.): 5S-19S
18. Welborn TA, Reid CM, Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 1997; 46 (1 Suppl.): 35-9
19. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications: Pt 1. diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus on behalf of the American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 Jul; 20 (7): 1183-97
21. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467-75
22. Saves M, Chene G, Dellamonica P, et al. Incidence, prevalence, and pathogenic correlates of insulin resistance and lipodystrophy syndrome [abstract 682-T]. 9th Conference on Retroviruses and Opportunistic Infections, 2002 [online]. Available from URL: http://www.retroconference.org/2002/ [Accessed 2003 Jul 12]
23. Smeaton L, DeGruttola V, Robbins G, et al. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials 2001; 22: 142-59
24. Noor AM, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16: F1-8
25. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV Infection. J Acquir Immune Defic Syndr 2000; 23: 35-43
26. Besson C, Jubault V, Viard JP, et al. Ketoacidosis associated with protease inhibitor therapy. AIDS 1998; 12: 1399-400
27. Mellor-Pita S, Yebra-Bango M, Alfaro-Martinez J, et al. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis 2002; 34: 716-7
28. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932-7
29. Galli M, Cozzi-Lepri A, Ridolfo A, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med 2002; 162: 2621-8
30. Hadigan C, Corcoran C, Stanley T, et al. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000; 85: 35-41
31. Hadigan C, Corcoran C, Piecuch S, et al. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. J Clin Endocrinol Metab 2000; 85: 3544-50
32. Yarasheski K, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21: 209-16
33. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-4
34. Hruz PW, Murata H, Qui H, et al. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002; 51: 937-42
35. Schambelan M, Benson C, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-75
36. Leow M, Addy C, Mantzoros C. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961-76
37. Woerle H, Mariuz P, Meyer C, et al. Mechanisms for deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918-25
38. Gan SK, Samaras K, Thompson C, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51: 3163-9
39. Luzi L, Perseghin G, Tambussi G, et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am J Physiol Endocrinol Metab 2003; 284: E274-80
40. Yarasheski K, Reeds D, Schulte J, et al. Impaired insulin sensitivity in HIV infected individuals is associated with higher hepatic lipid content and visceral adiposity [abstract 757]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 [online]. Available from URL: http://www.retroconference.org/2003/ [Accessed 2003 Jul 12]
41. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13: 1000-2
42. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-7
43. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-43
44. The panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2002 Feb 4]
45. Moyle G, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16: 1341-9
46. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
47. John M, Moore C, James I, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-23
48. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286: 1945-8
49. Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000; 199: 253-62
50. A twelve-week evaluation of rosiglitazone in the treatment of HIV-associated hyperlipidemia [online]. Available from URL: http://www. ClinicalTrials.gov [Accessed 2003 Feb 27]
51. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART associated lipodystrophy (HAL): a randomized, double-blind, placebo-controlled study [abstract LB13]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 [online]. Available from URL: http://www.retroconference.org/2002/ [Accessed 2003 Jul 12]
52. Sutinen J, Hakkinen AM, Westerbacka J. Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8: 199-207
53. Gelato M, Mynarcik D, Quick J, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002; 31: 163-70
54. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy. Ann Intern Med 2004; 140: 786-94
55. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363: 429-38
56. Adult AIDS Clinical Trials Group. AACTG recommendations for metabolic problems: guide covers insulin resistance and diabetes. AIDS Alert 2003 Jan; 18 (1): 6
57. Botella JI, Valero MA, Munoz V, et al. Complete resolution of protease inhibitor induced diabetes mellitus. Clin Endocrinol 2000; 52: 241-3
58. Martinez E, Coget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-10
59. Duncan MH, Singh BM, Wise PH, et al. A simple measure of insulin resistance. Lancet 1995; 346: 120-1
60. Martinez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46
61. Moyle G, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1 positive persons: single-arm observational cohort. J Acquir Immune Defic Syndr 2001; 28: 399-401
62. Domingo P, Matias-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001; 184: 1197-201
63. Wanke C, Falutz J, Shevitz A, et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002; 34: 248-59
64. Moyle G. Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. AIDS Patient Care and STDs 2002; 16 (12): 585-97
65. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35: 475-81
66. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38 (10): 1664-74
67. Nystrom T, Bratt G, Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med 2002; 252: 570-4
68. Joint Workgroup of the ADA and NIDDKD. The prevention or delay of type 2 diabetes: ADA and NIDDKD Position Statement. Diabetes Care 2002; 24: 742-749
69. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17: 1179-93
70. Hadigan C, Shafali J, Anderson E, et al. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human inmunodeficiency virus infection and fat redistribution. Clin Infect Dis 2001; 33: 710-7
71. van Leeuwen R, Katlama C, Murphy R, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 2003; 17: 987-99